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A comparison is made between microsomal NADPH-dependent Hz02 production and malondialdehyde 
(MDA) formation in rat liver microsomes, obtained from phenobarbital pretreated rats. An increase in 
Hz02 formation was observed during NADPH-dependent disposition (10 min) of 100 PM diazepam (33%) 
and 2 mM hexobarbital (69%). In contrast orphenadrine (100 PM) and its mono-N-demethylated 
metabolite tofenacine (100 pM) decreased the Hz02 formation (35% and 55070, respectively). However, all 
these substrates were found to inhibit NADPH-dependent lipid peroxidation (60 min), estimated by 
measuring MDA formation, to various extents. These data strongly suggest hat the oxidase activity of 
cytochrome P450 (Hz02 production) is not involved in a rate-limiting step in NADPH-dependent lipid 
peroxidation. 
Cytochrome P450 oxidase 
1. INTRODUCTION 
Three types of biochemical reactions have been 
established in which the cytochrome P450 system is 
involved [l]. The stoichiometry of these functions 
of cytochrome P450 is shown in fig.1. The mono- 
oxygenase function of cytochrome P450 has been 
studied extensively. The exact function and 
mechanism of the oxidase and peroxidase activity 
of cytochrome P450 is unknown. With regard to 
the oxidase activity however, it has been suggested 
RH + NADPH + H’ + O2 - ROH + NAOP’ * Hz0 m0”00xyge”aSe 
NAOPH + -i* + 0, - NAOP’ + H,O, oxldase 
RH + XOOH - ROH t XOH perox’dase 
Fig. 1. Proposed stoichiometry of the monooxygenase, 
oxidase and peroxidase functions of cytochrome P450: 
RH, ROH and XOOH are the substrate, the product and 
a peroxy compound, respectively. 
that the Hz02 formed during drug metabolism, 
originates from the decay of oxycytochrome P450, 
via superoxide anion radicals [2]. Since the parti- 
cipation of several reduced forms of oxygen in 
NADPH-dependent lipid peroxidation has been 
proposed [3,4], the oxidase activity of cytochrome 
P450 might be involved in microsomal lipid per- 
oxidation. In fact, cytochrome P450 has indeed 
been suggested to catalyze the propagation of lipid 
peroxidation [5]. However, the catalytic role of 
cytochrome P450 in peroxidation of lipid in liver 
microsomes as well as the participation of super- 
oxide anion radicals in microsomal lipid per- 
oxidation has also been challenged [6-S]. 
Here, we compared the effect of several cyto- 
chrome P450 substrates on the oxidase activity of 
cytochrome P450 with their effect on NADPH- 
dependent lipid peroxidation. In this way the in- 
volvement of the oxidase activity in a rate-limiting 
step of NADPH-dependent microsomal lipid per- 
oxidation was excluded. Furthermore, the results 
emphasize the regulatory function of substrates in 
the oxidase activity of cytochrome P450. 
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2. MATERIALS AND METHODS 
2.1. Chemicals 
Orphenadrine and tofenacine were generous 
gifts from Gist-Brocades (Delft) and diazepam a 
gift from Hoffmann-La Roche (Mijdrecht). Hex- 
obarbital (Evipan@ -Natrium) was from Bayer 
(Leverkusen); thiobarbituric acid (monohydrate) 
from E. Merck (Darmstadt); NADP+, glucose 
6-phosphate (disodium salt), glucose 6-phosphate 
dehydrogenase and catalase (from beef liver) were 
obtained from Boehringer (Mannheim). All other 
chemicals used were of analytical grade purity. 
2.2 Preparation of microsomes and pretreatment 
of animals 
Hepatic microsomes were prepared from 
250-300 g male Wistar rats as in [9]. Pheno- 
barbital treatment consisted of 3 daily i.p. injec- 
tions (80 mg/kg). On day 4 the rats were killed by 
decapitation. 
2.3. Enzyme assays 
The incubation conditions were essentially iden- 
tical for all measurements. Microsomes (from 
l/12 g liver/ml incubate) were incubated at 37°C 
with shaking air being freely admitted. The in- 
cubate (in 50 mM phosphate buffer (pH 7.4) with 
0.1 mM EDTA unless stated otherwise) contained 
0.5 mM NADP+, 4.2 mM MgC12, 4.2 mM glucose 
6-phosphate, 0.3 IU/ml incubate of glucose 
6-phosphate dehydrogenase and substrate. The 
substrate concentrations and the incubation times 
were as indicated in the figures. 
The Hz02 was determined as formaldehyde 
which is formed in the presence of methanol 
(50 mM) by the peroxidative reaction of catalase 
(3000 mu) according to [lo]. Formaldehyde was 
determined according to [ 111. 
Lipid peroxidation was determined by measur- 
ing malondialdehyde by means of the thio- 
barbituric acid assay, according to [ 121. The con- 
centration of malondialdehyde was calculated us- 
ing an extinction coefficient of 1.56 x 
lo5 M-’ . cm-‘. 
Microsomal protein was assayed as in [ 131, using 
crystalline bovine serum albumin as standard. 
3. RESULTS 
A linear rate of Hz02 formation is observed in 
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Fig.2. (A) The percentage change in Hz02 production 
using an incubation time of 10 min: (1) diazepam 
(100 PM); (2) hexobarbital (2 mM); (3) orphenadrine 
(100 pM); (4) tofenacine (100 pM). Hepatic microsomes 
of rats which were pretreated with phenobarbital were 
used. Data represent the mean (k SD) of at least 2 
duplicate experiments. 
Fig.2. (B) The percentage decrease in malondialdehyde 
using an incubation time of 60 min. The incubation was 
performed in an EDTA-free phosphate buffer medium; 
further as in fig.2A. 
a liver microsomal suspension in the presence of an 
NADPH generating system in the absence of 
substrate (fig.3). The Hz02 formation thus obtain- 
ed represents endogenous Hz02. Depending on the 
substrate used, the Hz02 production can either be 
decreased or activated (fig.2A). Diazepam 
(100 PM) enhanced Hz02 formation. Hexobarbital 
(2 mM) which is known to stimulate Hz02 produc- 
tion [14] was used as a reference compound. In 
contrast 100 PM of orphenadrine or its N- 
demethylated metabolite, tofenacine, attenuated 
the endogenous Hz02 formation by -35% and 
55070, respectively (fig.2A). Such a drastic inhibi- 
tion of H202 generation had not been reported; 
therefore, we evaluated this further by in- 
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Fig.3. Time-dependent Hz02 formation in liver 
microsomes obtained from rats which were pretreated 
with phenobarbital. The concentration-dependent in- 
hibitory effect of tofenacine is indicated. Data represent 
the mean of 3 expt. 
vestigating the dose-dependent inhibition of Hz02 
formation by tofenacine as a function of time 
(fig. 3). Endogenous Hz02 formation could ap- 
parently not be inhibited completely, since supple- 
mentation of the incubate with 200pM of 
tofenacine resulted in the same inhibitory effect as 
compared with 100 ,uM of tofenacine (not shown). 
Furthermore, a comparison was made between 
the effect of these compounds on Hz02 formation 
and on NADPH-dependent lipid peroxidation. 
The latter was measured by estimation of malon- 
dialdehyde (MDA). All substrates used were found 
to inhibit MDA formation. Again tofenacine was 
chosen to investigate this inhibition further (fig.4). 
The data show that the microsomal MDA forma- 
tion, promoted by NADPH, could be blocked ex- 
tensively by tofenacine in a concentration- 
dependent manner. Tofenacine at 200 ,LJM in- 
hibited NADPH-dependent MDA formation com- 
pletely (not shown). 
4. DISCUSSION 
Three main items with regard to the oxidase ac- 
tivity of cytochrome P450 (fig. 1) have thus far not 
Z’OopM 
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Fig.4. Time-dependent malondialdehyde formation in 
liver microsomes incubated in an EDTA-free phosphate 
buffer. Liver microsomes were obtained from rats which 
were pretreated with phenobarbital. The concentration- 
dependent inhibitory effect of tofenacine is indicated. 
Data represent he mean of 3 duplicate experiments. 
been solved unambiguously. These items are: what 
is the mechanism of endogenous NADPH- 
dependent Hz02 formation (Hz02 formation 
without substrate), what regulates the ‘uncoupling’ 
effect of substrates on the cytochrome P450 reac- 
tion cycle (Hz02 formation with substrate) and 
finally what is the biological effect of microsomal 
Hz02 (or superoxide anion radical) formation. 
It has been suggested that the Hz02 originates 
from the decay of oxycytochrome P450 in com- 
bination with the subsequent disproportionation of 
the superoxide anion radicals released [2]. The con- 
tribution of NADPH cytochrome P450 reductase 
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to the microsomal endogenous Hz02 formation 
has not been firmly established. However, the one- 
electron reduction of oxygen, forming superoxide 
anion radicals, may be directly catalyzed by the 
reductase [15,161. Superoxide anions thus formed 
may dismutate to H202. 
This finding, that both orphenadrine and 
tofenacine substantially decreased endogenous 
Hz02 formation, obviously provides an interesting 
tool to further investigate the intrinsic regulation 
of the oxidase activity. The observation that 
tofenacine cannot inhibit Hz02 formation com- 
pletely, indeed suggests that several mechanisms 
are involved in endogenous Hz02 production. The 
inhibition is not due to an effect on the 
catalase/H202/methanol reaction (unpublished). 
Moreover, NADPH-dependent cytochrome c 
reduction remains uninfluenced by orphenadrine 
or tofenacine (not shown). The fact that orphena- 
drine and tofenacine, in the presence of NADPH 
form a metabolic intermediate which irreversibly 
binds to ferrouscytochrome P450 [17] is not 
responsible for the inhibition of the oxidase 
activity: 
(1) Because orphenadrine and tofenacine produce 
this complexation of cytochrome P450 to a dif- 
ferent extent [17], whereas the inhibition of 
Hz02 formation is approximately of the same 
magnitude (fig.2A). 
(2) In [18] using benzphetamine as substrate a lack 
of relationship between NADPH catalyzed 
ferrouscytochrome P450 complexation and 
benzphetamine-induced increase of Hz02 pro- 
duction was shown. 
Tofenacine elicits a ligand binding with hepatic 
microsomal ferricytochrome P450 obtained from 
phenobarbital pre-treated rats [ 191. This inter- 
action might prevent oxygen binding and thereby 
impede cytochrome P450 catalyzed oxygen activa- 
tion. Further detailed mechanistic aspects of the 
extrinsic regulation of the oxidase activity are 
hardly known [20]. 
Here, emphasis was placed on the biological ef- 
fect of the oxidase activity of cytochrome P450. It 
has frequently been suggested that ‘activated’ ox- 
ygen species are involved in lipid peroxidation 
[3,4]. However, comparison of Hz02 formation 
with microsomal malondialdehyde formation 
demonstrates that both phenomena are not inter- 
connected (fig.2-4). This strongly suggests that the 
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oxidase activity or the interaction of superoxide 
anion with Hz02 (via the iron catalyzed 
Haber-Weiss reaction) is not responsible for a 
rate-limiting step in NADPH-dependent lipid 
peroxidation. 
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